@article{ffc59e8a7b064295a2a2d1fac4ee48ea,
title = "High-sensitivity C-reactive protein levels and pregnancy outcomes in women with unexplained infertility after ovarian stimulation with intrauterine insemination in a multicenter trial",
abstract = "Objective: To determine if chronic inflammation, assessed by basal high-sensitivity C-reactive protein (hs-CRP) levels, is associated with pregnancy outcomes in women with unexplained infertility undergoing ovarian stimulation with intrauterine insemination. Design: Prospective cohort analysis of the Reproductive Medicine Network's Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) randomized controlled trial. Setting: Multicenter university-based randomized controlled trial. Patient(s): A total of 781 couples with unexplained infertility. Intervention(s): Secondary analysis. Main Outcome Measure(s): Adjusted risk ratios of live birth, clinical pregnancy, and pregnancy loss rates by hs-CRP levels. Result(s): Associations between hs-CRP levels and clinical pregnancy rates were not observed after adjustment for baseline body mass index. There were fewer live births among women with higher hs-CRP levels, although confidence intervals crossed 1.0. The risk of pregnancy loss was greater in women with increased hs-CRP levels (1–3 mg/L: risk ratio [RR], 1.67; 95% confidence interval [CI], 1.00–2.79; >3–10 mg/L: RR, 1.84; 95% CI, 1.06–3.20; and >10 mg/L: RR, 2.14; 95% CI, 1.05–4.36 compared to women with hs-CRP <1 mg/L). Conclusion(s): This investigation suggests that chronic inflammation may increase the risk of pregnancy loss but not impact the clinical pregnancy rate in women with unexplained infertility undergoing ovarian stimulation with intrauterine insemination. Associations between inflammation and pregnancy outcomes in women with infertility merit further investigation. Clinical Trial Registration Number: clinicaltrials.gov NCT01044862.",
keywords = "Unexplained infertility, high-sensitivity C-reactive protein, live birth, ovarian stimulation, pregnancy loss",
author = "{NICHD Reproductive Medicine Network} and Gavrizi, {Sarah Z.} and Sushila Arya and Peck, {Jennifer D.} and Knudtson, {Jennifer F.} and Diamond, {Michael P.} and Wild, {Robert A.} and Hansen, {Karl R.}",
note = "Funding Information: Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (U10 HD077680) and the National Institute of General Medical Sciences (U54GM104938). The AMIGOS trial was supported by grants from the NICHD (U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10 HD055925) and by the American Recovery and Reinvestment Act. Funding Information: Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (U10 HD077680) and the National Institute of General Medical Sciences (U54GM104938). The AMIGOS trial was supported by grants from the NICHD (U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10 HD055925) and by the American Recovery and Reinvestment Act. S.Z.G. has nothing to disclose. S.A. has nothing to disclose. J.D.P. has nothing to disclose. J.F.K. has nothing to disclose. M.P.D. reports grants from Yale University and NIH/NICHD for the submitted work; he is on the board of directors and is a stockholder of Advanced Reproductive Care. R.A.W. has nothing to disclose. K.R.H. reports grants from the National Institutes of Health during the conduct of the study; grants from Roche Diagnostics, Ferring, and Ablacare, outside the submitted work. Funding Information: S.Z.G. has nothing to disclose. S.A. has nothing to disclose. J.D.P. has nothing to disclose. J.F.K. has nothing to disclose. M.P.D. reports grants from Yale University and NIH/NICHD for the submitted work; he is on the board of directors and is a stockholder of Advanced Reproductive Care. R.A.W. has nothing to disclose. K.R.H. reports grants from the National Institutes of Health during the conduct of the study; grants from Roche Diagnostics, Ferring, and Ablacare, outside the submitted work. Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = mar,
doi = "10.1016/j.xfre.2022.01.001",
language = "English (US)",
volume = "3",
pages = "57--62",
journal = "F and S Reports",
issn = "2666-3341",
publisher = "Elsevier BV",
number = "1",
}